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Abstract
Background: Hypoxia-inducible factor-1α (HIF-1α) plays an essential role in oxygen homeostasis.
The expression of HIF-1α-inducible genes is associated with tumor progression. p21 mediates cell
cycle arrest and is one of the downstream genes targeted by HIF-1.
Patients and methods: We examined the relationship between HIF-1α and p21 expression,
apoptosis and tumor progression using tissue specimens obtained surgically from 126 patients with
gastric cancer.
Results: Immunohistochemical analysis indicated that loss of p21 expression correlated positively
with patient age and tumor size. Lymph node metastasis was significantly more frequent in tumors
with loss of p21 expression (P = 0.022). HIF-1α-positive/p21-negative tumors had a lower
apoptotic index than any other tumor samples, and patients with HIF-1α-positive/p21-negative
tumors also had a significantly poorer prognosis than the other patient populations.
Conclusion:  These results suggest that loss of HIF-1α-dependent p21 expression results in
decreased apoptosis, increased cell survival and more aggressive tumors.
Background
The unregulated growth of cancer cells often results in
hypoxic conditions in tumor cell masses. Tumor hypoxia
results from an imbalance between elevated consumption
of oxygen in the rapidly cycling tumor cells and insuffi-
cient oxygen supply due to the lack of a physiological vas-
cular network. Multicellular organisms have evolved
cellular mechanisms that mediate a cascade of adaptive
molecular responses to hypoxia. HIF-1α is a transcription
factor that activates gene expression by binding to the
hypoxia responsive element (HRE), a cis-acting DNA
sequence present upstream of several genes essential for
the cellular response to hypoxia [1]. HIF-1α-responsive
genes also function in the glycolysis pathway and in
hematopoiesis and angiogenesis, through all of which
cells acquire an hypoxia-adapted metabolism and
increased oxygen supply [2]. Recently, HIF-1α has
emerged as a key regulator in the growth of gastric cancer
[3].
Apoptosis is an evolutionarily conserved cell death mech-
anism that also occurs in the adaptive cellular response to
hypoxic stress. Apoptosis, too, is an important safeguard
against tumor development. Tumors that exhibit loss of
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the p53 tumor-suppressor gene exhibit reduced levels of
hypoxia-induced cell death and an associated increase in
tumor progression [4]. The p21 gene (WAF1) was cloned
in a genetic screen for downstream effectors of p53 and
separately in a screen for upstream regulators of cyclin-
dependent kinases (CDKs) as CDK-interacting protein
(CIP1) [5]. The p21 promoter can be transactivated by
HIF-1 in a human prostate cancer cell line, indicating that
p21 is an HIF-1 target gene [6]. Furthermore, hypoxia-
induced p21 expression was abrogated in cells lacking
HIF-1α, but not in parental cells [7].
HIF-1α may therefore promote both cell survival and
growth arrest through the induction of hypoxia-respon-
sive genes. In the present study, we examined the role of
HIF-1α in hypoxic control of tumor progression, by exam-
ining the relationship between HIF-1α expression, p21
expression and apoptosis in tissue specimens from
patients with gastric cancer.
Materials and methods
Clinical materials
Subjects were 126 patients with gastric cancer (85 men, 41
women; age range, 27 to 88 years; mean age, 65.2 years)
who underwent gastrectomy at our institution in 1994.
Curative resection was performed in 77 patients and non-
curative resection in 49. Resected tissue specimens were
fixed in a 10% formaldehyde solution and embedded in
paraffin. Sections (4 μm thickness) were mounted on
glass slides. All samples were examined macroscopically
and histologically, based on criteria proposed by the Gen-
eral Rules for the Gastric Cancer Study [8]. Histological
examination was carried out on tissue preparations
stained with hematoxylin and eosin (H&E). In the current
study, tumors were divided into two histological types:
differentiated type, comprising papillary adenocarcinoma
and tubular adenocarcinoma, and undifferentiated type,
comprising poorly differentiated adenocarcinoma, signet
ring cell carcinoma, and mucinous adenocarcinoma. Two
paraffin blocks were prepared for all patients" one con-
taining both tumor tissue and adjacent normal tissue, and
the other containing tumor tissue invading to the deepest
level of the stomach wall.
Immunohistochemical staining
All specimens were immunostained with a monoclonal
antibody against p21WAF1/CIP1  (SX118, diluted 1:50,
DAKO, Glostrup, Denmark), p53 (Do-7, diluted 1:50,
DAKO, Glostrup, Denmark), and HIF-1α (NB 100–105,
diluted 1:100, Novus Biologicals, Littleton, CO, USA)[9].
After deparaffinization and rehydration, the slides for p21
and p53 immunostaining were autoclaved in citrate
buffer (0.01 M, pH 6.0) at 120°C for 10 minutes; 0.001 M
EDTA (pH 8.0) was used for HIF-1αimmunostaining to
facilitate reactivity of the fixed embedded tissue antigen
with the antibody. Endogenous peroxidase was blocked
by incubating the samples in methanol containing 0.3%
hydrogen peroxide for 10 minutes. Samples were then
rinsed in phosphate-buffered saline (PBS) and incubated
with normal rabbit serum for 30 minutes. Sections were
incubated with the aforementioned primary antibodies
for 2 hours at room temperature, then rinsed three times
in PBS. For detection, we used a Histofine SAB-PO (M) kit
(Nichirei Corp., Tokyo, Japan). The sections were then
incubated with biotinylated rabbit anti-mouse immu-
nogloblin (Ig; IgG, IgA, and IgM; Nicchirei Corp) for 10
minutes, washed three times in PBS and treated with per-
oxidase-conjugated streptavidin for 10 minutes. After a
final washing in PBS, the peroxidase label was detected by
incubating the sections in diamino-benzidine tetrahydro-
chloride (DAB) for 3 minutes. Nuclear counter-staining
was done using Mayer's hematoxylin solution. For nega-
tive controls, primary antibodies were replaced with non-
immune, normal serum. Automated immunohistochem-
istry was also carried out to support the immunostaining
described above, using a Ventana Discovery™ System
(Ventana Medical Systems, Inc., Tucson, AZ, USA).
Evaluation of immunostaining
p21 protein was present in the nuclei of tumor cells (Fig-
ure 1A). In some cases, normal gastric mucosa expressed
p21 protein, and nuclear staining could be detected in the
superficial reaches of the tumor, but not in the deeper
regions. We counted the number of p21-positive cells in
the whole tumor section, and evaluated the number of
p21-postive cells according to the depth of layers. The pat-
tern of HIF-1α immunostaining in the tumor was nuclear
and/or cytoplasmic (Figure 1B). Nuclear staining of HIF-
1α was absent in normal tissue excluding cytoplasmic
staining. In all samples, p53 protein was undetectable in
normal tissue, and present in the nuclei of tumor cells
(Figure 1C). A cell with nuclear immunostaining for p21,
p53 or HIF-1α (weak or strong) was scored as positive.
Based on these criteria, areas of focal staining with the
highest percentage of p53- and p21-positive nuclear stain-
ing within deep tumor tissue were estimated. A tumor was
scored as p21- or p53-positive when more than 10% of
the tumor cells had nuclear staining, in keeping with pre-
vious reports [10]. HIF-1α expression was frequently evi-
dent in regions around the invading edges of the tumor,
and necrotic areas such as those close to a deep ulcer. We
scored tumors as positive for HIF-1α overexpression if
nuclear staining was detected in more than 10% of the
tumor cells, irrespective of cytoplasmic reactivity at any
level [9,11].
Evaluation for apoptosis
We scored apoptotic cells as those showing the typical
characteristics of apoptosis when tissue specimens were
stained with H&E (Figure 1D). Apoptotic cells were iden-World Journal of Surgical Oncology 2006, 4:94 http://www.wjso.com/content/4/1/94
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tified based on the characteristic features of apoptosis:
compaction and migration of nuclear and cell outlines,
nuclear fragmentation and protuberance, and the pres-
ence of apoptotic bodies [12]. Apoptotic cells were
counted in tissue specimens from all patients. Five high-
power fields (×400) with the most abundant distribution
of tumor cells were selected for counts and between 1000
and 1500 tumor cells were counted. The apoptotic index
A) p21 expression in adjacent tumor tissue Figure 1
A) p21 expression in adjacent tumor tissue. Nuclear immunostaining is evident (original magnification, 100×). B) HIF-1α 
expression in invading regions of tumor. Variability in intensity of nuclear immunostaining is evident, accompanied by cytoplas-
mic staining (original magnification, 100×). C) Nuclear immunostaining of p53 in tumor tissue (original magnification, 100×). D) 
Tumor tissue stained with H&E (original magnification, 200×). Tumor tissue contains cells (arrow) with characteristic features 
of apoptosis.World Journal of Surgical Oncology 2006, 4:94 http://www.wjso.com/content/4/1/94
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was then calculated as the percentage of apoptotic cells.
Areas with extensive necrosis were avoided. A single
pathologist at each institution reviewed the slides and
counted apoptotic cells according to the criteria described
above.
Statistical analysis
The BMDP Statistical Package program (BMDP, Los Ange-
les, CA) for IBM (Armonk, NY) 3090 mainframe comput-
ers were used for all statistical analyses [13]. Data sets
were compared by chi-square and Student's t-tests using
the BMDP 4F and 3S programs. The BMDP 1L program
was used to analyze survival time using the Kaplan-Meier
method. Statistical significance was set at the P < 0.05
level.
Results
p21 expression and clinico-pathologic factors
Table 1 shows the correlation of the expression or loss of
expression of p21 with several clinico-pathologic factors.
Overall, 71 (56.3%) of the 126 tumor specimens were
negative for p21 expression. In tumors from patients
under 65 years of age, loss of p21 expression was signifi-
cantly more frequent than in tumors from patients over
the age of 65 (P = 0.026). Loss of p21 expression was sig-
nificantly more frequent in tumors with large size (P =
0.03), as compared to smaller tumors. With regard to
metastases, tumors with loss of p21 expression tended to
show increased frequency of lymphatic invasion (P =
0.089, Table 1) and a significantly higher frequency of
lymph node metastasis (P = 0.022, Table 2) than p21-
expressing tumors. Table 3 shows the relationship
between p21 expression, and the expression of p53 and
HIF-1α. Overexpression of p53 was detected in 57
(45.2%) tumors, and HIF-1α overexpression was detected
in 49 (38.9%) tumors. Immunohistochemical analysis
did not reveal a correlation between p21 expression and
p53 expression, or p21 and HIF-1α overexpression (P =
0.444 and 0.609, respectively).
Apoptosis associated with HIF-1α and p21 expression
The mean apoptotic index of all 126 tumors was 8.95 ±
6.24 (range 0–37). Tumors were divided into four differ-
ent populations based on HIF-1α and p21 expression and
the mean apoptotic index for each group was calculated
(Table 4). Tumors that were HIF-1α-positive/p21-nega-
tive had the lowest apoptotic index. There was a signifi-
cant difference between tumors that were HIF-1α-
positive/p21-negative, and those that were HIF-1α-nega-
tive/p21-negative (P = 0.037).
Clinical outcome associated with HIF-1α and p21 
expression
The mean follow-up time for patients was 55 ± 28 (± 1
S.D.) months (range, 1–82 months). The 5-year survival
rate of patients with p21-negative tumors was lower than
that of p21-positive tumors, but the difference was not
statistically significant (data not shown). The 126 patients
were again divided into four populations based on HIF-
1α expression and p21 expression, and we examined the
relationship between HIF-1α expression and prognosis in
p21-positive or -negative tumor samples. Table 5 shows
the 1-, 3- and 5-year survival rates for patients and the cor-
relation with HIF-1α and p21 expression. Patients with
HIF-1α-positive/p21-negative tumors had a significantly
poorer prognosis than the other study populations. In
particular, in patients with HIF-1α-positive tumors, those
who had lost expression of p21 had a significantly poorer
prognosis than those with p21 expression (P = 0.042).
Discussion
Our findings show that loss of p21 expression correlated
positively with younger patient age, and larger tumor.
Moreover, many patients with p21-negative tumors had
lymph node metastasis when compared to those with
p21-positive tumors, at a significantly higher frequency.
These results suggest that the loss of expression of p21 is
involved in the processes of tumor growth and metastasis,
in agreement with previously reports [14,15].
HIF-1α overexpression has been linked to a poor clinical
outcome in some types of human cancers [16-18]. How-
ever, some reports have suggested that tumor expression
of HIF-1α does not confer a survival advantage [18,19].
Although most of the HIF-1 target genes can promote
tumor growth through their enhanced expression, HIF-1-
activated genes, including p21, also have the potential to
inhibit growth under hypoxic conditions [20,21]. Ectopic
expression of HIF-1α in endothelial cells resulted in up-
regulation of p21, reduction of CDK activities, cell cycle
arrest at the G0/G1 check point, and subsequent apoptosis
[22]. In the current study, we found that apoptotic cells
were under-represented in HIF-1α-positive/p21-negative
tumors. Under hypoxic conditions, HIF-1α may inhibit
tumor proliferation through p21-mediated cell cycle con-
trol, resulting in the selection of cells that are resistant to
apoptosis and anti-cancer treatments. Most tumor cells
retain the ability to undergo apoptosis in response to
hypoxic stress [23]. When the apoptotic response to
hypoxia is lost, emerging tumor cells may be more resist-
ant to treatment and may therefore contribute to subse-
quent tumor relapse [24]. The mechanisms by which
hypoxia selects for cells resistant to apoptosis is unclear,
but the involvement of the p53 mutation has been exam-
ined [25]. Reports have shown that hypoxia inhibits cell
growth, and may cause apoptosis through a p53-depend-
ent pathway [26]. HIF-1α has also been shown to pro-
mote p53-dependent apoptosis [27], but other studies
have shown that growth arrest in response to hypoxia is
p53-independent [26]. In the current study, we found noWorld Journal of Surgical Oncology 2006, 4:94 http://www.wjso.com/content/4/1/94
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evidence of a relationship between p53 and p21 expres-
sion. We also evaluated the relationship between HIF-1α
and p53 expression to cell apoptosis, but found no statis-
tical significance between HIF-1α and p53 expression
(data not shown). Our previous study showed that the
combination of HIF-1α overexpression with nonfunc-
tional p53 tended to indicate a dismal prognosis [28].
In patients with HIF-1α-positive tumors, the correlation
between loss of p21 expression and poor clinical outcome
may reflect a physiological difference in the ability of p21-
positive versus p21-negative tumors to survive under
hypoxic conditions. Although HIF-1α-dependent tran-
scriptional activation has been associated with tumor
growth, our results suggest that concomitant expression of
p21 and HIF-1α may retard tumor growth to some degree.
The molecular mechanism underlying HIF-1α expression
in cancer warrants particular attention [29]. The wide-
spread occurrence of upregulated HIF-1α in common can-
cers and the involvement of hypoxia pathways in tumor
angiogenesis certainly argue for its importance and wide
applicability. Chemotherapy and radiation that target
HIF-1α may be effective and realistic, and in fact, this
approach has been reported [30]. However, the qualita-
tive and quantitative differences in the hypoxic response
of different cell types are not well known [31]. Further
research is therefore required in order to evaluate the
effects of HIF-1-mediated pathways on cell proliferation
and apoptosis in human cancers under hypoxic microen-
vironments.
In the present study, we showed that HIF-1α overexpres-
sion and loss of p21expression in gastric cancers corre-
lated with poor patient prognosis, compared to tumors
Table 1: Relationship between p21 expression and clinico-pathologic factors
Factors p21(+) (n = 55) p21(-) (n = 71) P value
Age (years)
<65 20 40 0.026
65 35 31
Gender
Male 38 47 0.731
Female 17 24
Depth of invasion
t1 33 35 0.231
t2,3,4 22 36
Histology
Differentiated 35 39 0.325
Undifferentiated 20 32
Tumor size
<3 cm 23 22 0.03
3 cm 22 49
Lymphatic invasion
Negative 26 23 0.089
Positive 29 48
Venous invasion
Negative 42 57 0.595
Positive 13 14
Table 2: Relationship between p21 expression and metastasis
p21-negative tumor (%) P value
Lymph node metastasis
Negative 36/75(48.0) 0.022
Positive 35/51(68.6)
Liver metastasis
Negative 68/122(55.7) 0.447
Positive 3/4(75.0)
Peritoneal dissemination
Negative 62/112(55.4) 0.525
Positive 9/14(64.3)World Journal of Surgical Oncology 2006, 4:94 http://www.wjso.com/content/4/1/94
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that retained p21 expression, or had lost HIF-1α expres-
sion. A potential mechanism for this was suggested by the
finding that apoptotic cells were under-represented in
HIF-1α-positive/p21-negative tumors. Aggressive tumors
that fail to induce p21 in an HIF-1α – dependent manner
may have increased cell survival without apoptosis, and
contribute to a poor prognosis for patients.
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